what's trending

5 most popular innovation stories in Houston this week

A roundup of business events to attend this January was among this week's top trending InnovationMap stories. Photo via Getty Images

Editor's note:Another week has come and gone, and it's time to round up the top headlines from the past few days. Trending Houston tech and startup news on InnovationMap included Houston innovation events, startups starting the year with fresh funding, and more.


7 can't-miss Houston business and innovation events for January

Check out these seven innovation events in Houston this month. Photo via Getty Images

It's a new year, and it's time to look at what's on the agenda this month for Houston innovators.

Here's a roundup of events not to miss this January — like workshops, summits, meetups, and more. Read more.


Houston biotech company closes IPO in $15.25M deal

A Houston biotech startup focused on developing therapeutics for neurodegenerative and autoimmune diseases has closed its IPO. Photo via Getty Images

A clinical-stage biotech company based in Houston has announced the closing of its $15.25 million IPO.

Coya Therapeutics, now trading under the ticker COYA, announced this week that its IPO — previously disclosed in December — has closed its initial public offering of 3,050,000 shares of its common stock and accompanying warrants to purchase up to 1,525,000 shares of common stock, per a news release.

The company is developing proprietary therapies to enhance the function of regulatory T cells to target systemic inflammation and neuroinflammation. Read more.

10 Houston startups start 2023 with fresh venture capital funding

Here are the 10 Houston startups that closed venture capital investment in the fourth quarter of last year. Photo via Getty Images

Houston startups saw a busy last quarter when it came to funding in 2022. From seed to series C, 10 Houston startups wrapped up the year with investment round closings.

In case you missed some of these headlines, InnovationMap has rounded up these 10 deals based on previous reporting. Scroll through to see which Houston startups are catching the eyes — and cashing the checks — of investors. Read more.

Texas population shatters records with massive new number milestone

We're welcoming more and more new Texans every day. Photo via Getty Images

The adage "everything's bigger in Texas" has never been more apropos than with this news: For the first time ever, the population of Texas officially reached 30 million.

Or 30,029,572 in July 2022, to be exact, according to the U.S. Census Bureau’s Vintage 2022 national and state population estimates, released on December 22. Read more.

Houstonian and serial entrepreneur plans to scale nonprofit fintech tool

The sky's the limit for DonateStock, Co-Founder and CEO Steve Latham says. Photo courtesy of DonateStock

Donating stock can be a smart way to offload assets and optimize a donation — but Steve Latham thought it was so cumbersome a process that it didn't even feel worth it.

"It was such a hassle that I never did it again," says Latham on the Houston Innovators Podcast.

That opportunity for innovation stuck with Latham as he advanced his career in AdTech in New York before moving back to Houston a few years ago. A serial entrepreneur, Latham was an early co-founder of the Houston Technology Center.

His latest venture is DonateStock — a tech platform that simplifies stock donation for both the donor and the beneficiary. The early version of Latham's vision was to clear up the lack of communication the original process had — nonprofits receiving stock donations were never notified about who made each donation. Read more.

Trending News

Building Houston

 
 

A Rice research team is tapping into materials science to better understand Alzheimer’s disease, a UH professor is developing a treatment for hereditary vision loss, and a BCM researcher is looking at stress and brain cancer. Photo by Gustavo Raskosky/Rice University

Research, perhaps now more than ever, is crucial to expanding and growing innovation in Houston — and it's happening across the city right under our noses.

In InnovationMap's latest roundup of research news, three Houston institutions are working on life-saving health care research thanks to new technologies.

Rice University scientists' groundbreaking alzheimer's study

Angel Martí (right) and his co-authors (from left) Utana Umezaki and Zhi Mei Sonia He have published their latest findings on Alzheimer’s disease. Photo by Gustavo Raskosky/Rice University

According to the Centers for Disease Control and Prevention, Alzheimer’s disease will affect nearly 14 million people in the U.S. by 2060. A group of scientists from Rice University are looking into a peptide associated with the disease, and their study was published in Chemical Science.

Angel Martí — a professor of chemistry, bioengineering, and materials science and nanoengineering and faculty director of the Rice Emerging Scholars Program — and his team have developed a new approach using time-resolved spectroscopy and computational chemistry, according to a news release from Rice. The scientists "found experimental evidence of an alternative binding site on amyloid-beta aggregates, opening the door to the development of new therapies for Alzheimer’s and other diseases associated with amyloid deposits."

Amyloid plaque deposits in the brain are a main feature of Alzheimer’s, per Rice.

“Amyloid-beta is a peptide that aggregates in the brains of people that suffer from Alzheimer’s disease, forming these supramolecular nanoscale fibers, or fibrils” says Martí in the release. “Once they grow sufficiently, these fibrils precipitate and form what we call amyloid plaques.

“Understanding how molecules in general bind to amyloid-beta is particularly important not only for developing drugs that will bind with better affinity to its aggregates, but also for figuring out who the other players are that contribute to cerebral tissue toxicity,” he adds.

The National Science Foundation and the family of the late Professor Donald DuPré, a Houston-born Rice alumnus and former professor of chemistry at the University of Louisville, supported the research, which is explained more thoroughly on Rice's website.

University of Houston professor granted $1.6M for gene therapy treatment for rare eye disease

Muna Naash, a professor at UH, is hoping her research can result in treatment for a rare genetic disease that causes vision loss. Photo via UH.edu

A University of Houston researcher is working on a way to restore sight to those suffering from a rare genetic eye disease.

Muna Naash, the John S. Dunn Endowed Professor of biomedical engineering at UH, is expanding a method of gene therapy to potentially treat vision loss in patients with Usher Syndrome Type 2A, or USH2A, a rare genetic disease.

Naash has received a $1.6 million grant from the National Eye Institute to support her work. Mutations of the USH2A gene can include hearing loss from birth and progressive loss of vision, according to a news release from UH. Naash's work is looking at applying gene therapy — the introduction of a normal gene into cells to correct genetic disorders — to treat this genetic disease. There is not currently another treatment for USH2A.

“Our goal is to advance our current intravitreal gene therapy platform consisting of DNA nanoparticles/hyaluronic acid nanospheres to deliver large genes in order to develop safe and effective therapies for visual loss in Usher Syndrome Type 2A,” says Naash. “Developing an effective treatment for USH2A has been challenging due to its large coding sequence (15.8 kb) that has precluded its delivery using standard approaches and the presence of multiple isoforms with functions that are not fully understood."

BCM researcher on the impact of stress

This Baylor researcher is looking at the relationship between stress and brain cancer thanks to a new grant. Photo via Andriy Onufriyenko/Getty Images

Stress can impact the human body in a number of ways — from high blood pressure to hair loss — but one Houston scientist is looking into what happens to bodies in the long term, from age-related neurodegeneration to cancer.

Dr. Steven Boeynaems is assistant professor of molecular and human genetics at Baylor College of Medicine. His lab is located at the Jan and Dan Duncan Neurological Research Institute at Texas Children’s Hospital, and he also is a part of the Therapeutic Innovation Center, the Center for Alzheimer’s and Neurodegenerative Diseases, and the Dan L Duncan Comprehensive Cancer Center at Baylor.

Recently, the Cancer Prevention and Research Institute of Texas, or CPRIT, awarded Boeynaems a grant to continue his work studying how cells and organisms respond to stress.

“Any cell, in nature or in our bodies, during its existence, will have to deal with some conditions that deviate from its ideal environment,” Boeynaems says in a BCM press release. “The key issue that all cells face in such conditions is that they can no longer properly fold their proteins, and that leads to the abnormal clumping of proteins into aggregates. We have seen such aggregates occur in many species and under a variety of stress-related conditions, whether it is in a plant dealing with drought or in a human patient with aging-related Alzheimer’s disease."

Now, thanks to the CPRIT funding, he says his lab will now also venture into studying the role of cellular stress in brain cancer.

“A tumor is a very stressful environment for cells, and cancer cells need to continuously adapt to this stress to survive and/or metastasize,” he says in the release.

“Moreover, the same principles of toxic protein aggregation and protection through protein droplets seem to be at play here as well,” he continues. “We have studied protein droplets not only in humans but also in stress-tolerant organisms such as plants and bacteria for years now. We propose to build and leverage on that knowledge to come up with innovative new treatments for cancer patients.”

Trending News